Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients

被引：0
|
作者：
Ryuji Takahashi
Uhi Toh
Nobutaka Iwakuma
Miki Takenaka
Hiroko Otsuka
Mina Furukawa
Teruhiko Fujii
Naoko Seki
Akihiko Kawahara
Masayoshi Kage
Satoko Matsueda
Yoshito Akagi
Akira Yamada
Kyogo Itoh
Tetsuro Sasada
机构：
[1] Kurume University School of Medicine,Department of Surgery
[2] Kurume University School of Medicine,Research Center for Innovative Cancer Therapy
[3] Kurume University School of Medicine,Department of Pathology
[4] Kurume University School of Medicine,Department of Immunology and Immunotherapy
来源：
Breast Cancer Research | / 16卷
关键词：
Overall Survival; Eribulin; Intrinsic Subtype; Median Overall Survival Time; Personalized Peptide Vaccination;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients
    Takahashi, Ryuji
    Toh, Uhi
    Iwakuma, Nobutaka
    Takenaka, Miki
    Otsuka, Hiroko
    Furukawa, Mina
    Fujii, Teruhiko
    Seki, Naoko
    Kawahara, Akihiko
    Kage, Masayoshi
    Matsueda, Satoko
    Akagi, Yoshito
    Yamada, Akira
    Itoh, Kyogo
    Sasada, Tetsuro
    [J]. BREAST CANCER RESEARCH, 2014, 16 (04)
  • [2] Immunological evaluation of personalized peptide vaccination for metastatic breast cancer patients with triple-negative types.
    Takahashi, Ryuji
    Toh, Uhi
    Iwakuma, Nobutaka
    Otsuka, Hiroko
    Shirouzu, Kazuo
    Matsueda, Satoko
    Shichijo, Shigeki
    Sasada, Tetsuro
    Itoh, Kyogo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients
    Kawano, Kouichiro
    Tsuda, Naotake
    Matsueda, Satoko
    Sasada, Tetsuro
    Watanabe, Noriko
    Ushijima, Kimio
    Yamaguchi, Tomohiko
    Yokomine, Masato
    Itoh, Kyogo
    Yamada, Akira
    Kamura, Toshiharu
    [J]. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2014, 36 (03) : 224 - 236
  • [4] Personalized treatment in metastatic triple-negative breast cancer: The outlook in 2020
    Azim, Hamdy A.
    Ghosn, Marwan
    Oualla, Karima
    Kassem, Loay
    [J]. BREAST JOURNAL, 2020, 26 (01): : 69 - 80
  • [5] Metastatic Triple-negative Breast Cancer
    Rakha, E. A.
    Chan, S.
    [J]. CLINICAL ONCOLOGY, 2011, 23 (09) : 587 - 600
  • [6] Metastatic Triple-Negative Breast Cancer
    Zhang, Xiaojie
    Yeung, Kay T.
    [J]. CURRENT BREAST CANCER REPORTS, 2023, 15 (03) : 288 - 297
  • [7] Metastatic Triple-Negative Breast Cancer
    Xiaojie Zhang
    Kay T. Yeung
    [J]. Current Breast Cancer Reports, 2023, 15 : 288 - 297
  • [8] A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
    Zhang, Qingyuan
    Shao, Bin
    Tong, Zhongsheng
    Ouyang, Quchang
    Wang, Yuting
    Xu, Guoying
    Li, Shaorong
    Li, Huiping
    [J]. BMC MEDICINE, 2022, 20 (01)
  • [9] A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
    Qingyuan Zhang
    Bin Shao
    Zhongsheng Tong
    Quchang Ouyang
    Yuting Wang
    Guoying Xu
    Shaorong Li
    Huiping Li
    [J]. BMC Medicine, 20
  • [10] Metastatic triple-negative breast cancer: A population based study
    Ess, S.
    Jochum, W.
    Oehlschlaegel, C.
    Thuerlimann, B.
    [J]. BREAST, 2011, 20 : S78 - S78
12345